Advancements in technology are impacting many aspects of
clinical research, opening doors to innovative study designs and
clinical operations that may not have been possible even five
years ago. This is especially true when evaluating the potential
of emerging technology for home-based assessments, as
a component of observational or interventional research.

Michael F Murphy MD PhD, chief medical and scientific

officer at Worldwide Clinical Trials, explores the implications of
‘siteless’ clinical trials for patients and researchers, the range
of potential clinical assessments within these studies, and key
considerations for exploiting this emerging opportunity.